Skip to main content
Fig. 1 | Trials

Fig. 1

From: A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial

Fig. 1

Study schematic. BE, bronchiectasis; BRONCH-UK, UK Bronchiectasis Registry; EMBARC, European Multicentre Bronchiectasis Audit and Research Collaboration; NIHR, National Institute for Health Research; NICRN, Northern Ireland Clinical research Network; HTS, hypertonic saline; QoL-B, Quality of Life - Bronchiectasis; HRQoL, health-related quality of life; QALY, quality-adjusted life year; SGRQ, Saint George’s Respiratory Questionnaire

Back to article page

Trials

ISSN: 1745-6215